Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Mahesh Basyal"'
Autor:
Nicholas J. Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D. Dinardo, Gautam Borthakur, Nitin Jain, Maro Ohanian, Elias Jabbour, Ghayas C. Issa, Wei Qiao, Xuelin Huang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Prithviraj Bose, Farhad Ravandi, Ricardo Delumpa, Regina Abramova, Guillermo Garcia-Manero, Michael Andreeff, Jorge Cortes, Hagop Kantarjian
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-11 (2023)
Abstract Background Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedista
Externí odkaz:
https://doaj.org/article/ad7ca09609614d58a1b068a42eba3a40
Autor:
Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, Hussein A. Abbas, Sanam Loghavi, Gautam Borthakur, Musa Yilmaz, Ghayas C. Issa, Samuel I. Dara, Mahesh Basyal, Li Li, Kiran Naqvi, Rasoul Pourebrahim, Elias J. Jabbour, Steven M. Kornblau, Nicholas J. Short, Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi, Joseph Khoury, Naval Daver, Hagop M. Kantarjian, Michael Andreeff, Courtney D. DiNardo
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-6 (2023)
Abstract In TP53 wild-type acute myeloid leukemia (AML), inhibition of MDM2 can enhance p53 protein expression and potentiate leukemic cell apoptosis. MDM2 inhibitor (MDM2i) monotherapy in AML has shown modest responses in clinical trials but combini
Externí odkaz:
https://doaj.org/article/e09e6500217f443ab08d9d78cb583310
Autor:
Weiguo Zhang, Guopan Yu, Hongying Zhang, Mahesh Basyal, Charlie Ly, Bin Yuan, Vivian Ruvolo, Sujan Piya, Seemana Bhattacharya, Qi Zhang, Gautam Borthakur, Venkata Battula, Marina Konopleva, William G. Rice, Michael Andreeff
Publikováno v:
Haematologica, Vol 108, Iss 6 (2022)
Strategies to overcome resistance to FMS-like tyrosine kinase 3 (FLT3)-targeted therapy in acute myeloid leukemia (AML) are urgently needed. We identified autophagy as one of the resistance mechanisms, induced by hypoxia and the bone marrow microenvi
Externí odkaz:
https://doaj.org/article/fc214a4663764cf4a1afa569299e8742
Autor:
Li Li, Muharrem Muftuoglu, Shaoheng Liang, Mahesh Basyal, Jiangxing LV, Mehmet Emin Akdogan, Ken Chen, Michael Andreeff, Christopher R. Flowers, Simrit Parmar
Publikováno v:
JCI Insight, Vol 7, Iss 7 (2022)
SARS-CoV-2 vaccines pose as the most effective approach for mitigating the COVID-19 pandemic. High-degree efficacy of SARS-CoV-2 vaccines in clinical trials indicates that vaccination invariably induces an adaptive immune response. However, the emerg
Externí odkaz:
https://doaj.org/article/3e123eb9e0664b438e3bf1797556bd8a
Autor:
Yannan Jia, Weiguo Zhang, Mahesh Basyal, Kyung Hee Chang, Lauren Ostermann, Jared K. Burks, Charlie Ly, Hong Mu-Mosley, Qi Zhang, Xin Han, William E. Fogler, John L. Magnani, Arnaud Lesegretain, Anna A. Zal, Tomasz Zal, Michael Andreeff
Publikováno v:
Leukemia.
Autor:
Yannan Jia, Weiguo Zhang, Mahesh Basyal, Kyung Hee Chang, Lauren Ostermann, Jared Burks, Charlie Ly, Hong Mu-Mosley, Qi Zhang, Han Xin, William Fogler, John Magnani, Arnaud Lesegretain, Anna Zal, Tomasz Zal, Michael Andreeff
CXC chemokine receptor 4 (CXCR4)/CXC motif ligand 12 (CXCL12) and E-(endothelial)-selectin/E-selectin ligands (E-selectin-L) axes play critical roles in leukemia cell homing to the bone marrow niche and are closely associated with resistance to FLT3-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2eb3f66ac813d65c5511565c9307dd3f
https://doi.org/10.21203/rs.3.rs-2277452/v1
https://doi.org/10.21203/rs.3.rs-2277452/v1
Autor:
Edward Ayoub, Vakul Mohanty, Yuki Nishida, Tallie Patsilevas, Mahesh Basyal, Russell Pourebrahim, Muharrem Muftuoglu, Ken Chen, Ghayas C. Issa, Michael Andreeff
Publikováno v:
Blood Cancer Discovery. 4:A41-A41
TP53 mutations in acute myeloid leukemia (AML) are associated with copy number abnormalities (CNA), structural variants and high risk of relapse (Döhner et al., 2017; Giacomelli et al., 2018; Bernard et al. 2020). In spite of relatively high remissi
Publikováno v:
Blood Cancer Discovery. 4:A05-A05
Targeted therapies(TT) combining FLT3 inhibitors with hypomethylating agents (HMA) and Venetoclax (Ven) are highly effective against FLT3-ITD acute myeloid leukemia (AML) with high response rates. Signaling mutations along with emergence of rarer mut
Publikováno v:
Blood Cancer Discovery. 4:A07-A07
Acute myeloid leukemia (AML) represents a heterogeneous hematopoietic disorder characterized by accumulation of immature hematopoietic precursors with differentiation block. FLT3 internal tandem duplications (FLT3-ITD) are commonly occurring genetic
Autor:
Muharrem Muftuoglu, Musa Yilmaz, Mahesh Basyal, Li Li, Takahiko Seki, Arnaud Lesegretain, Naval Daver, Michael Andreeff
Publikováno v:
Blood. 140:2273-2274